TheraRadar
Data updated: Mar 29, 2026

BUCAPSOL

BUSPIRONE HYDROCHLORIDE
Cardiovascular Approved 2025-03-13

Bucapsol (buspirone hydrochloride) is an anxiolytic indicated for the management of anxiety disorders or the short-term relief of anxiety symptoms. Its efficacy has been specifically demonstrated in patients with symptoms corresponding to Generalized Anxiety Disorder (GAD), including those with coexisting depressive symptoms. It is intended for the treatment of persistent anxiety (typically lasting at least one month) rather than the routine tension or stress associated with everyday life.

Source: FDA Label โ€ข EPIC PHARMA LLC

How BUCAPSOL Works

The precise mechanism of action of buspirone is not fully understood. It differs from benzodiazepines in that it does not exert effects on GABA receptors. Buspirone exhibits a high affinity for serotonin 5-HT1A receptors, where it acts as a partial agonist. It also possesses moderate affinity for dopamine D2 receptors. This unique profile results in anxiolytic effects without significant sedation, muscle relaxation, or anticonvulsant activity.

Source: FDA Label
1
Indication
--
Phase 3 Trials
1
Years on Market

Details

Status
Prescription
First Approved
2025-03-13
Routes
ORAL
Dosage Forms
CAPSULE

Companies

Active Ingredient: BUSPIRONE HYDROCHLORIDE

BUCAPSOL Approval History

Loading approval history...

What BUCAPSOL Treats

2 indications

BUCAPSOL is approved for 2 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Anxiety Disorders
  • Generalized Anxiety Disorder
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

BUCAPSOL FDA Label Details

Pro

Indications & Usage

Bucapsol TM capsules are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride relieved anxiety in the presence of these coexisting depr...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.